JP2017522384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522384A5 JP2017522384A5 JP2017524097A JP2017524097A JP2017522384A5 JP 2017522384 A5 JP2017522384 A5 JP 2017522384A5 JP 2017524097 A JP2017524097 A JP 2017524097A JP 2017524097 A JP2017524097 A JP 2017524097A JP 2017522384 A5 JP2017522384 A5 JP 2017522384A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- cancer
- protein
- igg
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1413240.1 | 2014-07-25 | ||
| GBGB1413240.1A GB201413240D0 (en) | 2014-07-25 | 2014-07-25 | Method |
| PCT/EP2015/065895 WO2016012285A2 (en) | 2014-07-25 | 2015-07-10 | Method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522384A JP2017522384A (ja) | 2017-08-10 |
| JP2017522384A5 true JP2017522384A5 (enExample) | 2018-08-23 |
| JP6708641B2 JP6708641B2 (ja) | 2020-06-10 |
Family
ID=51587261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524097A Active JP6708641B2 (ja) | 2014-07-25 | 2015-07-10 | 方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10973889B2 (enExample) |
| EP (2) | EP3171891B1 (enExample) |
| JP (1) | JP6708641B2 (enExample) |
| KR (2) | KR20230119267A (enExample) |
| CN (2) | CN106714834A (enExample) |
| AU (1) | AU2015294125B2 (enExample) |
| BR (1) | BR112017001420A2 (enExample) |
| CA (1) | CA2955704A1 (enExample) |
| CL (1) | CL2017000191A1 (enExample) |
| CO (1) | CO2017000571A2 (enExample) |
| DK (1) | DK3171891T3 (enExample) |
| EA (1) | EA039169B1 (enExample) |
| ES (1) | ES3054696T3 (enExample) |
| FI (1) | FI3171891T3 (enExample) |
| GB (1) | GB201413240D0 (enExample) |
| HR (1) | HRP20251560T1 (enExample) |
| IL (1) | IL249981B (enExample) |
| LT (1) | LT3171891T (enExample) |
| MX (1) | MX2017001138A (enExample) |
| MY (1) | MY196858A (enExample) |
| PL (1) | PL3171891T3 (enExample) |
| PT (1) | PT3171891T (enExample) |
| RS (1) | RS67520B1 (enExample) |
| SG (1) | SG11201700172WA (enExample) |
| SI (1) | SI3171891T1 (enExample) |
| WO (1) | WO2016012285A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| CA3149395A1 (en) * | 2019-08-01 | 2021-02-04 | Memorial Sloan-Kettering Cancer Center | Cells for improved immunotherapy and uses thereof |
| EP4096691A1 (en) | 2020-01-28 | 2022-12-07 | Freeline Therapeutics Limited | Improved assay for determining neutralising antibody titre to a viral vektor |
| GB202002072D0 (en) * | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| GB202003129D0 (en) * | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN120078887A (zh) * | 2020-09-21 | 2025-06-03 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4433587A2 (en) | 2021-11-15 | 2024-09-25 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| IL315305A (en) | 2022-03-17 | 2024-10-01 | Astrazeneca Ireland Ltd | Improved IgG-degrading enzymes and methods of using them |
| AU2023383441A1 (en) | 2022-11-18 | 2025-06-05 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| CN116087528A (zh) * | 2022-12-27 | 2023-05-09 | 华中科技大学同济医学院附属同济医院 | 一种sqtsm1蛋白在卵巢早衰的应用 |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025047848A1 (ja) | 2023-08-30 | 2025-03-06 | アステラス製薬株式会社 | ＩｄｅＺ改変体 |
| WO2025248469A1 (en) * | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | TREATMENT OF IgG-RELATED DISEASES |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| GB202413764D0 (en) | 2024-09-18 | 2024-10-30 | Genovis Ab | Immunoglobulin proteases and their uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| JPH0612624B2 (ja) * | 1984-06-20 | 1994-02-16 | 株式会社日立製作所 | 半導体集積回路装置 |
| US6006752A (en) * | 1996-05-09 | 1999-12-28 | The General Hospital Corporation | Mixed chimerism and tolerance |
| CN105770871A (zh) * | 2005-06-09 | 2016-07-20 | 汉莎医药有限公司 | IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途 |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| GB2427360A (en) * | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| CN102584989B (zh) * | 2007-09-14 | 2015-05-13 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物及纯化与检测IgG的方法和试剂盒 |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) * | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| TWI626491B (zh) * | 2012-12-10 | 2018-06-11 | 布萊恩荷登視覺協會 | 用於視力校正之具有一或多個多正焦區域之眼用光學透鏡 |
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
-
2014
- 2014-07-25 GB GBGB1413240.1A patent/GB201413240D0/en not_active Ceased
-
2015
- 2015-07-10 HR HRP20251560TT patent/HRP20251560T1/hr unknown
- 2015-07-10 IL IL249981A patent/IL249981B/en unknown
- 2015-07-10 DK DK15756845.2T patent/DK3171891T3/da active
- 2015-07-10 CN CN201580049441.3A patent/CN106714834A/zh active Pending
- 2015-07-10 SG SG11201700172WA patent/SG11201700172WA/en unknown
- 2015-07-10 EP EP15756845.2A patent/EP3171891B1/en active Active
- 2015-07-10 MY MYPI2017000280A patent/MY196858A/en unknown
- 2015-07-10 US US15/328,879 patent/US10973889B2/en active Active
- 2015-07-10 CN CN202210234712.4A patent/CN114949187A/zh active Pending
- 2015-07-10 WO PCT/EP2015/065895 patent/WO2016012285A2/en not_active Ceased
- 2015-07-10 PT PT157568452T patent/PT3171891T/pt unknown
- 2015-07-10 PL PL15756845.2T patent/PL3171891T3/pl unknown
- 2015-07-10 EP EP25199052.9A patent/EP4663755A3/en active Pending
- 2015-07-10 MX MX2017001138A patent/MX2017001138A/es unknown
- 2015-07-10 KR KR1020237026683A patent/KR20230119267A/ko not_active Ceased
- 2015-07-10 SI SI201532086T patent/SI3171891T1/sl unknown
- 2015-07-10 FI FIEP15756845.2T patent/FI3171891T3/fi active
- 2015-07-10 KR KR1020177005456A patent/KR102565244B1/ko active Active
- 2015-07-10 EA EA201790192A patent/EA039169B1/ru unknown
- 2015-07-10 BR BR112017001420A patent/BR112017001420A2/pt not_active Application Discontinuation
- 2015-07-10 ES ES15756845T patent/ES3054696T3/es active Active
- 2015-07-10 CA CA2955704A patent/CA2955704A1/en active Pending
- 2015-07-10 AU AU2015294125A patent/AU2015294125B2/en active Active
- 2015-07-10 LT LTEPPCT/EP2015/065895T patent/LT3171891T/lt unknown
- 2015-07-10 JP JP2017524097A patent/JP6708641B2/ja active Active
- 2015-07-10 RS RS20251260A patent/RS67520B1/sr unknown
-
2017
- 2017-01-24 CO CONC2017/0000571A patent/CO2017000571A2/es unknown
- 2017-01-25 CL CL2017000191A patent/CL2017000191A1/es unknown
-
2021
- 2021-03-03 US US17/191,634 patent/US12397044B2/en active Active
-
2025
- 2025-07-07 US US19/261,759 patent/US20260000739A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191210A5 (enExample) | ||
| KR102524613B1 (ko) | 시스테인 프로테아제 | |
| KR102524594B1 (ko) | 시스테인 프로테아제 | |
| US20230391820A1 (en) | Hydrophobic interaction protein chromatography under no-salt conditions | |
| JP6708641B2 (ja) | 方法 | |
| US20250230186A1 (en) | Stabilised Protein Solutions | |
| WO2019040671A1 (en) | METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT | |
| CA3227990A1 (en) | Isolation of therapeutic protein | |
| JP2023535842A5 (enExample) | ||
| US12577275B2 (en) | Hydrophobic interaction chromatography carrier and protein purification method | |
| US20230218825A1 (en) | Auto-injector assembly | |
| RU2832029C1 (ru) | Автоинъекторное устройство для подачи лекарственных препаратов | |
| JP7833407B2 (ja) | 薬剤を送達するための自動インジェクターデバイス | |
| NZ743923B2 (en) | Chimeric proteins and methods of immunotherapy | |
| WO2024057095A1 (en) | Mutant protease | |
| NZ743923A (en) | Chimeric proteins and methods of immunotherapy | |
| HK40062718A (en) | Hydrophobic interaction protein chromatography under no-salt conditions | |
| US20200147070A1 (en) | Inducing phospholipidosis for enhancing therapeutic efficacy | |
| NZ728265B2 (en) | Methods to enhance organ transplant and antibody therapies | |
| CN104955479A (zh) | 高温死端抗体过滤 | |
| WO2018132874A1 (en) | Method of preventing an immune response with alpha- 1 anti-trypsin |